Non-Hodgkin Lymphoma Archives - Page 25 of 26

Investigators demonstrated that the risk of histologic transformation appeared lower than for follic

Prolonged PFS With Brentuximab Vedotin in Cutaneous T Cell Lymphoma

By

June 8, 2017

Brentuximab vedotin significantly prolonged PFS with higher response rates compared with methotrexate or bexarotene among patients with CTCL.

Ibrutinib shows promise for reducing the severity of symptoms and steroid dose related to cGVHD, par

Lymphoma

Momelotinib for Previously Treated Patients With Myelofibrosis

By

Alexander M. Castellino, PhD

June 7, 2017

For patients with primary or secondary myelofibrosis who have already received ruxolitinib, momelotinib was significant in improving disease-related symptoms over best available therapy.

Lymphoma

Rituximab in the Treatment of Follicular Lymphoma: the Future of Biosimilars in the Evolving Therapeutic Landscape

By

J. Subramanian, J. Cavenagh, B. Desai, I. Jacobs

June 2, 2017

[Cancer Management and Research] This research summarizes the role of rituximab across the spectrum of FL treatment and the evolving therapeutic landscape with the emergence of novel agents currently in clinical development.

Cutaneous adverse events while receiving pembrolizumab has been linked with better treatment respons

Lymphoma

Rituximab for DLBCL May Double Risk of Subsequent AML

By

Jonathan Goodman, MPhil

May 25, 2017

Rituximab’s mechanism of action may reduce immune surveillance, allowing for the proliferation of cancer cells and infectious agents.

Patients who are treated for multiple myeloma at high-volume cancer centers have better survival out

Lymphoma

Patients With DLBCL at Elevated Risk of Non-cancer-related Death

By

Jonathan Goodman, MPhil

May 3, 2017

Patients with DLBCL were at an increased risk of non-cancer-related deaths from blood disease, infection, gastrointestinal disease, vascular diseases, and lung disease.